the blood during the earliest stages of cancer development. EarlyCDT®-Lung is a blood test that measures a panel of seven autoantibodies specific for lung cancer-associated antigens and is being utilized by physicians to assess the risk of a pulmonary nodule being malignant. The test's high specificity and positive predictive value (PPV) complements the high sensitivity of computed tomography (CT). As a 'rule in' test, EarlyCDT-Lung helps identify which patients with a pulmonary nodule(s) are most likely to have a lung cancer. Method: A cohort of nearly 2000 patients tested by EarlyCDT-Lung were followed up for clinical outcomes. Medical records were requested from physician offices and reviewed to determine clinical actions, nodule characteristics and any cancer diagnoses. Background: We analyzed both short-and long-term postoperative outcomes between patients with continuous nodal metastasis (NoSkip) compared to those with nodal skip-metastasis (Skip). Method: We retrospectively analyzed patients who underwent robotic-assisted video-thoracoscopic (RAVT) pulmonary lobectomy by one surgeon between September 2010 and May 2017. Patients with final pathology reporting pulmonary metastasis or benign lesion were excluded. Inclusion criteria consisted of obligatory pathologic mediastinal nodal (pN2) classification. Patients were then stratified into two groups: Skip or NoSkip. Patients' demographics, perioperative outcomes, perioperative complications, and overall survival (OS) were compared. Results: Of 423 total patients who underwent RAVT lobectomy, 390 patients had primary lung cancer (LC). While 319 patients with primary LC had pN0 or pN1 disease, 71 patients had pN2 disease, of which 18 (25.3%) were Skip and 53 (74.7%) were NoSkip. Mean age, gender distribution, and body habitus were similar between groups (p¼0. 617, p¼0.194 and p¼0.091, respectively). Patients with Skip had lower mean pre-operative forced expiratory volume in 1 second as percent of predicted (FEV1%; 79.5±3.5% vs. 89.7±2.8%), but this difference was not quite significant (p¼0.053). Albeit not significant, patients in the NoSkip group had slightly more intraoperative complications (15.1% vs. 5.6%) and slightly more often required conversion to thoracotomy (15.1% vs. 5.6%) compared to the Skip group
Background: Several studies have shown that NSCLC genomic background among Hispanics differs from other populations. The finding of low frequency genomic alterations in cfDNA to increase diagnostic accuracy in NSCLC could refine the treatment. We hypothesized that cfDNA can be an alternative or complement for detection of low frequency genomic targets. We aimed to understand the landscape of cfDNA-identified genomic drivers in a cohort of patients (pts) with NSCLC of Hispanic ancestry. Method: We collected data from 51 Hispanic pts (Mexico and Colombia) with advanced NSCLC (Stage III/IV) who previously underwent tissue screening for ALK, EGFR, and ROS1. CfDNA was extracted from plasma and analyzed by a commercial NGS test (Guardant360â) which detects genomic alterations (alts) in up to 73 genes. Results: Median age was 56 years (31-83). Most pts were female (64.7%) and never smokers (76.5%). 94% of cases (48/51) had cfDNA detectable alts with a mean number of 3.37 cfDNA alts per test (range, 1 -10). Of the 48 pts with cfDNA genomic alts, 23 (47.9%) had a known genomic driver (EGFR (27.4%), TP53 (13.7%), ALK (7.8%), KRAS (5.8%), and BRAF (3.9%)). Interestingly, cfDNA was able to detect some genomic alts previously undetected by tissue biopsy (either due to false negatives or to technical limitations such as insufficient or low-quality DNA). In the case of EGFR, 12 pts had EGFR alts through cfDNA which were previously undetected by tissue biopsy. Similarly, cfDNA detected 3 alterations in ALK which were previously undetected by tissue sample. Of 48 pts, 35.4% were switched to a targeted therapy as a result of alts detected through cfDNA, with adequate responses: disease control rate was 82.4% (partial response 47.2% and stable disease 35.2%) and progression free survival was 7.4 months (95%CI 2.6-28.1). Conclusion: In a selected population of young Hispanics (especially never smokers and women) with NSCLC the use of comprehensive cfDNA analysis allowed a treatment change September 2018 Abstracts S159
